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Summary Benznidazole is a lipophilic analogue of misonidazole (MISO) which shows promise as a
chemosensitizer for clinical use, particularly in combination with CCNU. We have investigated the detailed pharmacokinetics of benznidazole in mice, dogs and sheep to provide a data base for the estimation of doses
required for chemosensitization in man. Pharmacokinetic behaviour was linear except at high doses in mice.
Absorption was fairly rapid and bioavailability was complete following both i.p. administration in mice and
oral administration in dogs. Elimination t4 values were longer than for MISO, being 90min in mice, 4-5 h in
sheep and 9-11 h in dogs. At doses giving linear kinetics, peak whole plasma concentrations per administered
mgkg-1 were 0.75 jigml-1 for the i.p. route in mice and 1.8jugmlP' for the oral route in dogs. Though between 39 and 59% of plasma benznidazole was bound to protein, tissue penetration was generally good. Tissue/whole plasma ratios ranged from 59-99% for transplantable mouse tumours and from 14-70% for
spontaneous dog neoplasms. Nervous tissue penetration was similar to that in tumours: brain/whole plasma
ratios averaged between 61 and 76% in mice and 42% in dogs, while peripheral nerve/whole plasma ratios in
dogs averaged 74%. Mean liver/whole plasma ratios were 42% and 71% in BALB/c and C3H/He mouse
strains respectively. Only -5% of the administered dose was excreted unchanged in the urine, indicating the likelihood of extensive metabolism. These data show that benznidazole should have suitable pharmacokinetic
properties for clinical use as a chemosensitizer. Enhancement of CCNU response is likely to require circulating benznidazole concentrations of 10-30 pgml-1 and we predict that these will be obtained with oral
doses of 6-20mgkg- 1 in man.
Extensive studies have demonstrated that the
response of mouse tumours to cytotoxic drugs can
be enhanced by misonidazole (MISO) (1-(2-nitro-
imidazol-1-yl)-3-methoxypropan-2-ol, Ro 07-0582;
Roche) (for reviews see McNally, 1982; Siemann,
1982). This enhancement, or chemosensitization, is
usually greater than that seen in dose-limiting
normal tissues, resulting in an improved therapeutic
index. Because of the relatively high doses of MISO
usually required for chemosensitization in mice (see
above refs), and also because of its neurotoxicity in
man (Dische et al., 1977), we have been interested
in finding an improved chemosensitizer.
In a detailed study of the structure-activity
relationships for MISO analogues in combination
with the nitrosourea CCNU (1-(2-chloroethyl)-3-
cyclohexyl-l-nitrosourea) against the KHT tumour
(Workman & Twentyman, 1982) we found that
sensitizer lipophilicity was particularly impor-
tant for chemosensitization. The lipophilic ana-
logue benznidazole (N-benzyl-(2-nitroimidazolyl)
acetamide, Ro 07-1051; Radanil; Roche), the
structure of which is shown in Figure 1, was
selected for detailed study because of its ability to
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Figure 1 Structure of benznidazole.
chemosensitize at relatively low doses, and we
subsequently showed it to give a similar therapeutic
gain to that seen with much higher doses of MISO
(Twentyman & Workman, 1983). These findings
have been confirmed independently by Siemann et
al. (1983).
Although benznidazole is used quite widely in
South America to treat patients with the
trypanosomal infection Chagas' disease or with
mucotaneous Leishmaniasis (Barclay et al., 1978; Cerisola et al., 1978; Coura et al., 1978; Fava et al., 1978), apart from our preliminary studies (White et
al., 1982) the only published data on its pharmaco-
kinetics are for human plasma concentrations
measured by polarography (Raaflub & Ziegler,
1979; Raaflub, 1980). Here we describe the
pharmacokinetics of benznidazole in the mouse, sheep and dog, as determined by high-performance
liquid chromatography (HPLC). These data,
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particularly on plasma and tumour concentrations,
have been used as a basis for the estimation of the
benznidazole doses required in a Phase I trial of
benznidazole plus CCNU, at present ongoing in
our Unit.
Materials and methods
Animals and tumours
Adult inbred male BALB/c mice were obtained
from OLAC (Southern) Ltd. (Bicester, UK) and
adult inbred C3H/He mice of both sexes from
OLAC and our own breeding colony. Mice were
housed in plastic cages on sawdust bedding made
from soft white woods, and allowed laboratory
chow and water ad lib. They were used at 20-35 g
body wt. RIF-1 and EMT6 tumours were grown
intramuscularly (i.m.) in the gastrocnemius muscle
of the hind leg of C3H/He and BALB/c mice,
respectively, as described by Twentyman et al.
(1979). In some experiments EMT6 tumours were
grown intradermally (i.d.) in the flank (Twentyman
& Bleehen, 1975).
The sheep used were Clun Forest/Border
Leicester cross withers weighing about 35 kg. Non-
tumour bearing dogs were adult beagles weighing
9-10 kg or adult collie crossbreds weighing 19-
28kg. All were clinically normal with hepatic and
renal function and haematological parameters in
the normal range. Food was withheld overnight
before drug administration. A further seven dogs
bearing spontaneous tumours were presented for
treatment at the Department of Clinical Veterinary
Medicine.
Drug administration
Benznidazole was supplied in powder form by
Roche Laboratories (Welwyn Garden City, UK).
For most mouse studies the drug was suspended in
50% polyethylene glycol (MW400) in 0.85% saline
or Hanks' salt solution, and injected i.p. in a
volume of 5-10mlkg-1. In some experiments it was
dissolved in dimethyl sulphoxide and the solution
injected i.p. or i.v. in a volume of 1.25mlkg-1; in
another experiment it was injected i.p. as a
suspension in arachis oil. For top-up doses in
multiple dose experiments benznidazole was
dissolved in a mixture of polyethylene glycol (65%)
and propylene glycol (35%) to give a concentration
of lOmgml-1, and then diluted 1:10 with warm
Hanks' immediately before injection of the solution
in a volume of 10mlkg-1 (Twentyman &
Workman, 1983). A similar vehicle was used for i.v.
injection in dogs and sheep, but with saline
replacing Hanks'. Volumes of up to 5mlkg-1 of
this solution were injected slowly, over a few
minutes, via -the cephalic or carotid vein. For oral
administration in dogs',ienznidazole was packed
into gelatin capsules, size no. 00.
Benznidazole analysis
Procedures used for the collection of urine, blood
and tissues were similar to those described in detail
previously (Brown & Workman, 1980; White et al.,
1979, 1980; Workman, 1980a). In the mouse
studies bleeding was by cardiac puncture with
replicate animals sacrificed at each time-point. With
dogs and sheep serial samples were taken from the
same animals. For protein binding studies, plasma
ultrafiltrate was prepared using Ultra-free anti-
convulsant drug filter units (Millipore, Harrow)
(Workman & Brown, 1981) or the Amicon Micro-
partition system (Amicon, Woking) (Lee &
Workman, 1983). Concentrations of benznidazole
in plasma, ultrafiltrate, urine and tissue
homogenates (25%-33% w/v) were determined by
reversed-phase HPLC using an adaptation of the
method described previously for misonidazole
(Workman et al., 1978). Briefly, samples were
treated with 2 vol methanol containing the internal
standard 1-(2-nitroimidazol-1-yl)-3-ethoxypropan-2-
ol (RoO7-0913, Roche), and centrifuged at 5000g
for 20min with cooling to -15°C. The clear
supernatant was removed for analysis. This was
carried out using a modular HPLC system from
Waters (Milford, Mass, USA), fitted with a Radial
Compression Module or Z-Module. The column
used was a Waters Radial-PAK C18 cartridge
(8 mm i.d. containing 10pm spherical particles
loaded with octadecylsilane), and this was eluted
isocratically with 55 or 66% methanol/water at a
constant flow rate between 2.7 and 4mlmin-m. The
absorbance of the effluent was monitored at 313 nm.
Benznidazole was identified by co-chromatography
with authentic material. Quantitation was by peak
height ratio with reference to standard curves which
were linear over the range 0.2-1000pgml-'. For a
plasma concentration of 10pgml-l the coefficient
of variation was 2.5% (n=8). The lower limit of
quantitation was about 2 ng on-column,
representing a concentration of 0.2pgml-1 for a
20,l injection volume. There were no interfering
peaks in control specimens. The analysis time was
<2 min.
Pharmacokinetic parameters
These were calculated as described in detail
elsewhere (White & Workman, 1980; Workman &
Brown, 1981). Brief details are as follows. Plasma
elimination half-life (4') was calculated from the
equation t=ln 2/k, where k is the elimination rate
constant given by the slope of In concentration
versus time. Lines of best fit were fitted by leastPRECLINICAL PHARMACOKINETICS OF BENZNIDAZOLE 293
squares linear regression analysis. Areas under
plasma concentration x time curves were calculated
in one of two ways, as appropriate.
1 From the expression AUCO-_ =Co/k where C0
is the extrapolated concentration at time 0.
2 AUC from time 0 to time t was estimated by
Simpson's rule. The remaining AUC was given
by AUC(t C0)=Ctlk, where Ct is the
concentration at t. AUC(O - 0 was then obtained
by the sum ofAUC(O t) and AUC(O_o).
Statistical analysis was by Students' t-test.
Pharmacokinetic parameters were calculated on the
basis of drug concentrations in whole plasma (i.e.
protein bound plus free), unless stated otherwise.
Results
HPLC
Figure 2 shows a representative chromatogram of a
methanol extract of whole tumour from a BALB/c
mouse given benznidazole. With u.v. detection at
313 nm only a single peak was observed which was
not present in the tumour of control mice, and this
corresponded to the parent drug; thus there was no
evidence of metabolites. This was true for plasma,
urine and tissues of all species studied.
Plasma pharmacokinetics
Mouse Figure 3 shows representative whole
plasma pharmacokinetics for benznidazole given i.p.
to BALB/c mice as a suspension in 50% poly-
ethylene glycol at three different doses, 26, 78 and
650mgkg-1 (0.1, 0.3 and 2.5mmolkg-1). These
doses are similar to those used in our previous
chemosensitization studies (Workman &
Twentyman, 1982; Twentyman & Workman, 1983).
For the two lower doses absorption was rapid, with
peak concentrations occurring at 15-30min. The
elimination half-life (4f) was independent of dose
over this range. The t2 values obtained (with 95%
confidence limits) were 93 (83-106) min at
26mgkg-' and 96 (84-113) min at 68mgkg-'
(P>0.1). With the higher dose of 650mgkg-' peak
concentrations were achieved at 60min and
remained constant to at least 6 h before declining at
a much slower rate than at the lower doses. Similar
non-linear pharmacokinetic behaviour was seen
consistently in repeat experiments in both BALB/c
and C3H/He mice. After the highest dose the
concentration remaining at 24h (15pgml-' in the
experiment shown in Figure 3) was quite variable
between experiments, in some cases being
undetectable (<0.2,gml 1).
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Figure 2 HPLC of benznidazole in the methanol
extract of an EMT6 mouse tumour grown in the flank
of a BALB/c mouse. Benznidazole (650mgkg-1 i.p.)
was given 45 min previously. Peak 1 is the internal
standard (3 pgml-1 methanol) and peak 2 is
benznidazole (13.5pgml-1 homogenate; 54pgg-1
tumour). Chromatographic conditions: column,
Waters Radial-PAK C18 Cartridge; mobile phase, 60%
methanol/water; flow rate 4mlmin-1; column
pressure, 1500 p.s.i.; temperature, ambient; detection,
absorbance at 313 nm; sample volume, 20pM.
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Figure 3 Whole plasma pharmacokinetics of
benznidazole at different doses in BALB/c mice. ({j)
26mgkg-1, (0) 78mgkg-1, (0) 650mgkg-1. Bars
indicate 2s.e. (5 mice per point).294 P. WORKMAN et al.
For the experiment shown in Figure 3 the peak
whole plasma concentrations (+2 s.e.) were
18.0+3.7, 36.0+2.5 and 105+15pgml-' at 26, 78
and 650mgkg-1 respectively. This lack of
proportionality provides further evidence of non-
linear pharmacokinetics. Figure 4 illustrates the
results of an independent experiment to compare
the whole plasma benznidazole concentrations at
30min for a large number of doses ranging from
0.26-832 mgkg- 1 (0.001-3.2 mmolkg-1). The
lowest dose was chosen to give the minimum
detectable concentration and the highest dose was
about the maximum tolerated. Concentrations were
determined at 30min since this is the time at which
the cytotoxic agent is usually given in chemo-
sensitization experiments (Workman & Twentyman,
1982; Twentyman & Workman, 1983; Siemann et
al., 1983) and also corresponds to the time of the
peak for doses up to 78 mgkg-1 (Figure 3). It can
be seen that the relationship between whole plasma
concentration and dose was linear up to
26mgkg-', but the deviation from linearity became
progressively more marked with increasing dose
above this. The data in Figure 4 are in good
agreement with those in Figure 3, as well as with
those of several other experiments in both BALB/c
and C3H/He mice.
Experiments were also carried out in BALB/c
mice to compare the whole plasma pharmaco-
kinetics of benznidazole when given i.p. as a
suspension in 50% polyethylene glycol/saline with
those obtained after administration i.p. or i.v. as a
solution in dimethyl sulphoxide. Combined data
from four experiments are shown in Figure 5. With
i.v. benznidazole at 65mgkg-1 the concentrations
were very high at 2min, suggesting a rapid
distribution phase; otherwise the concentrations
declined exponentially with a t4 of 117 (91-162) min
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Figure 5 Effect of route of administration and vehicle
on the pharmacokinetics of benznidazole in whole
plasma of BALB/c mice. 0 65mgkg-1 i.v. in dimethyl
sulphoxide. A 32.5mgkg-' i.v. in dimethyl
sulphoxide. 0 65mgkg-' i.p. in dimethyl sulphoxide.
O 65mgkg'- i.p. in 50% polyethylene glycol/saline.
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Figure 4 Effect of benznidazole dose on the whole plasma concentration at 30min in BALB/c mice. Left-
hand panel: doses up to 26mg/kg-'. Right-hand panel: doses between 26 and 832mgkg-1. Bars indicate 2s.e.
(5 mice per point).
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(open circles and dotted line). A similar t- of 119
(100-150) min (P>0.1) was obtained with the lower
dose of 32.5mgkg-1 given in the same way (open
triangles and solid line). The data points for i.p.
administration of 65 mgkg- 1 in dimethyl
sulphoxide (closed circles) were initially lower but
subsequently higher than those for the same dose
given i.v. Those for 65mgkg-1 given i.p. in glycol
vehicle (harlequin circles) were still lower initially
but at later times were not as low as those for half
the dose given i.v. By comparing areas-under-curves
(AUCO .) we obtained i.p. bioavailabilities of 113%
and 87% for the dimethyl sulphoxide and glycol
vehicles respectively.
The extent of binding to plasma proteins in vitro
was 38% for BALB/c mice and 39% for C3H/He
mice. In one experiment we determined whole
plasma and whole blood concentrations in BALB/c
mice 45, 75, 105 and 135min after a dose of
650mgkg-' i.p. in arachis oil. The blood/whole
plasma concentration ratio was constant over this
period, with an overall mean ratio of 116+4% (s.e.,
n=16).
Dog Table I summarises the whole plasma
pharmacokinetic parameters in each of the non-
tumour bearing dogs investigated. Figure 6
1uu -
illustrates the pharmacokinetics of, benznidazole in
whole plasma for two dogs, each receiving the drug
orally and i.v. on different occasions. Figure 7
compares, for one of these dogs, the amount of free
drug (i.e. that present in the plasma ultrafiltrate)
with the total amount of drug (bound plus free).
The extent of protein binding was constant over
the entire time course (e.g. Figure 7), which was
normally - 24 h. Apart from the two i.v. time
courses, in vivo protein binding ranged from 52-
59%. The more extensive binding seen with i.v.
administration may possibly have been due to the
glycols in the vehicle.
With one exception where the absorption phase
was slow and prolonged (dog D at 12.5mgkg-1),
peak whole plasma concentrations were reached
between 1 and 5h after oral administration. Peak
concentrations of 50 gmlm' were readily achieved
with doses of 25-50mgkg-1, but the linear
correlation between peak and dose was poor.
For the larger, crossbred dogs the elimination t4
after oral administration was fairly reproducible
(range 9.5-11.2 h), although the prolonged
absorption in the above-mentioned dog gave rise to
a much longer apparent 4'. Somewhat shorter t4
values were obtained in the two beagles, which were
about half the weight of the larger dogs. The area-
under-the-curve (AUCO ) for the oral route was
roughly in proportion to dose among the crossbred
dogs, and was lower in the beagles.
When given i.v. at a dose of 5 mgkg'-I to dogs C
and D, the kinetics of benznidazole elimination
were biphasic. Insufficient early time points were di_
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Figure 6 Whole plasma pharmacokinetics of
benznidazole in dogs C (closed symbols) and D (open
symbols). Circles represent data for an oral dose of
25 mgkg - ', triangles an i.v. dose of 5 mgkg- '.
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Figure 7 Plasma pharmacokinetics of benznidazole in
dog C after an i.v. dose of 5mgkg-1. * free
benznidazole in plasma ultrafiltrate. 0 total
benznidazole (free+protein bound).
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Table 1 Summary ofpharmacokinetic parameters for benznidazole in dog whole plasma.
tjfl Proteina
Weight Dose (mgkg-1) Peak conc. Peak (95% confidence AUCO0_ binding
Dog Typec (kg) and route (,ugml ') time limits) (1ugml- h) (%)
A 1 18 25 oral 48.4 5h job -800b 53
B 1 28 25 oral 52.2 3h job -800b 59
25 oral 38.9 5 h 9.7 687 55
(8.9-10.6)
C 1 28 12.5 oral 26.5 1 h 11.2 419 n.d.
(9.7-13.3)
5 i.v. 12.7 5min 7.6 105 72+2
(7.1-8.1)
25 oral 46.5 3 h 9.7 804 53
(8.9-10.6)
D 1 20 12.5 oral 13.1 12h 19.4 450 n.d.
(17.3-22.0)
5 i.v. 12.4 5min 10.2 138 74+1
(9.2-11.4)
E 2 9 50 oral 59.8 Sh 5.7 760 55+3
(5.3-6.1)
F 2 10 50 oral 54.8 3 h 6.8 707 52+3
(6.4-7.3)
aWhere binding was determined over the full-time course, values given are the mean+s.e. (n=8).
Where no errors are shown, results are the mean of the 4 and S h values only.
bSamples were collected up to 9 h only.
'1 - Collie crossbred; 2 - Beagle.
obtained for a precise calculation of the distribution
phase half life (txa) but this was estimated by back-
stripping to be about 10-25 min. The elimination
phase half-life (tffi) was comparable to that for the
oral route (Table I). Plasma clearance values for
dogs C and D were 0.0476 and 0.03621h-'kg-'
respectively. After normalising for dose, comparison
of AUCO_A data for oral administration with those
for i.v. data in the same dogs gave an overall
bioavailability of about 130%: i.e., the availability
was greater with the oral route.
The volume of distribution (Vdarea) was calculated
from the total plasma i.v. data to be 0.52 and
0.531kg-1 for dogs C and D respectively; the
corresponding values calculated from unbound drug
data were 2.05 and 1.871kg-'.
Sheep Two sheep received an i.v. dose of
4mgkg-1. Protein binding (±s.e., n=6) was 41
±2% and 42+2% respectively. For whole plasma
benznidazQle, respective peak concentrations of 3.6
and 2.5jugml-' were obtained, and the elimination
t4 values (with 95% confidence limits) were 5.2 (4.1-
6.9) h and 3.8 (2.6-7.2) h.
Urinary excretion
Benznidazole was given i.p. to groups of five
BALB/c mice at a dose of 650mgkg-' and the 24h
urinary recoveries determined. Values obtained in
two experiments were 4.8 and 5.2% respectively.
Tumour and normal tissue penetration
Mice The data on the penetration of benznidazole
into the EMT6 and KHT mouse tumours are
summarised in Table II. Benznidazole was
administered either as a single i.p. dose with
sampling at 45, 75, 105 and 135 min for EMT6
(Brown & Workman, 1980), or in multiple i.p. doses
with sampling between 1 and 16 h for KHT
(Twentyman & Workman, 1983). The mean plasma
concentration did not vary by more than a factor of
two over the sampling period (Table II). For
simplicity the data are presented as tumour/whole
plasma ratios averaged over the entire sampling
period for each experiment. However, it should be
noted that whereas with KHT the ratios were
constant, with the shorter sampling period used for
EMT6 there was a tendency for the ratios to
increase with time. For example, in experiment b
(Table II) the tumour/whole plasma ratios (s.e.,
n=5) at 45, 75, 105 and 135min were 58+8%,
70+5%, 97+4% and 88 +9%, respectively. Thus
although the overall mean ratios in Table II are
lower for EMT6 than for KHT, the actual steady-
state values were very similar indeed.
In the second experiment with the KHT tumour,PRECLINICAL PHARMACOKINETICS OF BENZNIDAZOLE 297
of benznidazole into mouse
tumours.
Tumour/whole plasma ratio
(%±s.e.)
Tumour (site) Exp I Exp 2
EMT6 (i.d. flank)1 59+ga 79+5b
(n= 16) (n=20)
EMT6 (i.m. leg)' 75+5c 74+6d
(n=20) (n=20)
KHT (i.m. leg)2 99+3e 90+ 3f
(n=25) (n= 13)
aSingle dose of 650mgkg-' i.p.; sampling times 45, 75,
105 and 135 min (Brown & Workman, 1980); range of
mean plasma concentrations 49-99 ugmlg-1.
bDosing as a; range of mean plasma concentrations 77-
121 Mgml-'.
CDosing as a; range of mean plasma concentrations 100-
130,ugml-.
dDosing as a; range of mean plasma concentrations 74-
133 ugml-'.
'Priming dose of 60mgkg-1 i.p. followed by 15 hourly
doses of 15mgkg-' i.p. (Twentyman & Workman, 1983);
sampling times 1, 4, 8, 11 and 16h; range of mean plasma
concentrations 25-47Mgml- -.
fDosing as e but omitting the dose at 1 h; sampling
times 2, 4, 7, 8, 12 and 16h; range of mean plasma
concentrations 12-29Mugml-.
1BALB/c mice.
2C3H/He mice.
ratios were also determined at 1 h following single
i.p. doses of 78 and 260mgkg- 1: these were
respectively 88+5% and 88+2% (s.e., n=5), which
compare closely with the ratio of 90+3% (n=13)
for the multiple dose schedule.
As far as absolute tumour concentrations are
concerned, a single i.p. dose of 650mgkg-1 gave
peak levels of 55+11gg-g1 (s.e., n=4) and 104
±10gg-1 (n=5) for the two experiments with
EMT6 i.d. flank tumours, and 130+7pgg-1 (n=5)
and 84+14pgg-' (n=5) for the two with EMT6
i.m. leg tumours. (The lower level in the first flank
experiment was due to administration as a
suspension in arachis oil, which gives a
correspondingly lower plasma concentration than
50% polyethylene glycol). With the multiple dose
schedule steady-state concentrations in the KHT
tumour were 26 and 32Mgg-1 respectively.
In three of the experiments where single i.p. doses
of 650mgkg-' were given to BALB/c mice bearing
EMT6 tumours, whole brain concentrations of
benznidazole were also determined at the same time
(Brown & Workman, 1980). Overall mean
brain/whole plasma ratios are presented in Table III,
but, as for the EMT6 tumour, these tended to
increase over the sampling period: in experiment b,
for example, the ratios (±s.e., n=5) at 45, 75, 105
and 135min were 56+3%, 69+3%, 71+5% and 75
+5%, respectively. Brain/whole plasma ratios and
absolute brain concentrations were similar to those
for the EMT6 tumour in the same mice.
Tumour/brain ratios averaged between 99 and
120% (Table III).
Table III Penetration of benznidazole into whole brain
ofBALB/c mice bearing EMT6 tumours.
Brain/wholeplasma ratio Tumour/brain ratio
(%± s.e.) (%+s.e.)
Exp la 61+5 (n=16) 120+33 (n=16)
Exp 2" 68+3 (n=20) 116+5 (n=20)
Exp 3c 76+4 (n=20) 99+7 (n=20)
The superscripts a.b and c refer to footnotes shown in
Table II, and allow comparison with the tumour/plasma
ratios from the same experiment.
Three experiments were carried out to compare
liver and whole plasma concentrations 0.5, 3 and
6 h after an i.p. dose of 78 mgkg-1 (Table IV).
Liver/whole plasma ratios were fairly constant over
this period, averaging 42+4% (s.e., n=5) in
BALB/c mice and 71 +8% (n=29) in C3H/He mice.
Dogs Benznidazole was administered orally at a
dose of 12.5 mgkg-1 or, in one case, 25mgkg-' to
seven dogs bearing spontaneous neoplasms. Whole
plasma concentrations and protein binding were
similar to the results described earlier for normal
dogs. The tissue samples were taken between 1.67
and 4.5 h, the period when peak concentrations
usually occur (Table I), and the tissue benznidazole
concentrations and tissue/whole plasma ratios are
given in Table V. Most of the samples were from
primary or secondary tumour deposits, but in some
cases apparently normal tissues were also obtained.
In the case of the neoplastic tissues, penetration
of benznidazole was generally good, with
tissue/whole plasma ratios ranging from 14-70%.
The overall mean+s.e. for the 24 samples
(excluding cyst fluid) was 50+3%, and most of the
values were reasonably close to this figure. Some of
the lowest ratios were obtained for the mixed
mammary tumour (dog 4), which contained
particularly tough tissue; especially low ratios were
noted in the cystic area and cyst fluid. The spleen
metastasis of the metastatic mammary adeno-
carcinoma also had a low ratio. Inner and outer
areas of tumour were analysed in dogs 2 and 4, but
there was no consistent pattern. In terms of
Table II Penetration298 P. WORKMAN et al.
Table IV Penetration of benznidazole (78mgkg-' i.p.) into mouse liver.
BALBIc C3H/He
Time Whole plasma Liver Liver/whole plasma Wholeplasma Liver Liver/whole plasma
(h) (pgml 1) (j.sgg') (O) (mgml ') (Cgg') (o)
0.5 45.3 20.8 46.6 33.9 25.2 75.8
+3.3 +3.3 +7.2 +2.2 +2.2 +7.3
(n=5) (n=5) (n=5) (n= 10) (n= 10) (n=10)
3.0 29.8 10.3 34.8 34.1 17.3 53.3
+1.9 +1.8 +6.4 +1.6 +3.7 +12.2
(n=5) (n=5) (n=5) (n=10) (n=10) (n= 10)
6.0 12.2 8.2 43.9 21.1 17.8 84.3
+3.3 +1.6 +5.9 +1.2 +3.3 +17.6
(n=5) (n=5) (n=5) (n= 10) (n=9) (n=9)
Overall 41.7 70.6
+3.7 +7.5
(n= 15) (n=29)
Results are expressed as the mean+ s.e. of n determinations. BALB/c data are from one experiment; C3H
data pooled from two experiments.
absolute neoplastic tissue concentrations, the overall
mean+s.e. for the 24 samples taken between 1.67
and 4.5 h was 5.6+0.5pgg-1 (values from dog 3
were halved to normalise to a dose of
12.5 mgkg-1).
Although a low value was obtained for liver in
dog 6, the results for normal tissues were generally
similar to those for tumours. This included the
brain and peripheral nerve samples from dog 6. A
more extensive study of benznidazole penetration
into brain and peripheral nerve was carried out in
two non-tumour bearing dogs, and the results are
shown in Table VI. Plasma concentrations were
rather low for the oral dose of 25 mgkg-1,
particularly in one dog, and this was probably a
result of the general anaesthetic. Brain/whole
plasma ratios were fairly constant over the 1-4 h
period, with an overall mean of 42+3% (s.e.,
n= 8). Peripheral nerve/whole plasma ratios tended
to increase over the sampling period and the mean
of 74+7% (s.e., n=7) was higher than that for
brain.
Discussion
Although, compared with MISO, it exhibits similar
or slightly greater radiosensitization of hypoxic cells
(Adams et al., 1979; Anderson & Patel, 1979), the
clinical potential of benznidazole in cancer
treatment is as a chemosensitizer, particularly in
combination with CCNU. We have shown that to
obtain a given enhancement of tumour response to
CCNU the benznidazole dose required is much
lower than that for misonidazole (Workman &
Twentyman, 1982); moreover, the tumour
enhancement is greater than that seen in normal
tissues and the therapeutic gain with low dose
benzidazole is similar to that with high dose MISO
(Twentyman & Workman, 1983). Very similar
results were reported by Siemann et al. (1983). It
should be noted, however, that in multiple dose
experiments designed to simulate human pharmaco-
kinetics, Hirst et al. (1983) found that the
therapeutic gain with benznidazole was in certain
instances inferior to that for MISO.
When combined with melphalan benznidazole
gave greater enhancement of tumour response than
MISO but the evidence for a therapeutic gain was
equivocal (Sheldon & Batten, 1982; Twentyman &
Workman, 1983). With cyclophosphamide no
enhancement was seen by Twentyman & Workman
(1982), or McNally (personal communication), but
enhancement was observed by Chaplin et al. (1984
not published).
Reviewing the chemosensitization data overall,
we felt that the combination of benznidazole plus
CCNU showed the most promise for clinical use
(Twentyman & Workman, 1983). Particularly
important was the greater potency of benznidazole
compared to MISO, which suggested that nitro-
imidazole neurotoxicity might be avoided.
Moreover, prolonged daily administration of
benznidazole had been used to treat South
American patients with the trypanosomal infection
Chagas' disease or with mucotaneous Leishmaniasis
(Barclay et al., 1978; Cerisola et al., 1978; Coura et
al., 1978; Fava et al., 1978). The main objectives of
the present communication are: (i) to describe the
detailed pharmacokinetics of benznidazole; (ii) toPRECLINICAL PHARMACOKINETICS OF BENZNIDAZOLE 29
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Table VI Penetration of benznidazole into brain and peripheral nerve in two crossbred dogs
given an oral dose of 25 mgkg-1.
Benznidazole concentration (ugml or Mgg-1) (tissue/plasma ratio %)
Dog G Dog H
Time (h) Plasma Brain Peripheral nerve Plasma Brain Peripheral nerve
1 3.1 1.1 (35%) 1.3 (41%) 23.1 11.6 (50%) 14.0 (60%)
2 3.8 1.5 (39%) 3.4 (90%) 22.2 10.0 (45%) 15.5 (70%)
3 4.3 2.1 (49%) n.d. 18.7 8.5 (45%) 14.7 (78%)
4 4.1 1.1 (26%) 4.0 (96%) 18.5 7.9 (43%) 15.6 (84%)
n.d.=not determined.
relate the pharmacokinetic behaviour to chemo-
sensitization; and (iii) to illustrate how this data
base has been used for the estimation of the
benznidazole dose which might produce chemo-
sensitization in man.
Benznidazole showed considerable binding to
plasma proteins in all species studied: 39% in the
mouse, 59% in the dog, and 42% in the sheep.
These figures are comparable with those of 58%
(Workman & Brown, 1981) and 44% (Raaflub &
Ziegler, 1979) for human plasma and of 46% for
bovine serum albumin (Clarke & Wardman, cited
in Watts et al., 1980). Binding is probably to
hydrophobic sites on proteins, but hydrogen
bonding through the amide group may also occur
(Watts et al., 1980).
After i.v. administration to mice and dogs
benznidazole was cleared biphasically. However the
distribution phase was extremely short, and
negligible error would be introduced by the use of
the one-compartment model to calculate drug
clearance. With oral administration in the dog peak
plasma concentrations were attained rapidly
(usually 1-5 h) and bioavailability was complete.
Similar bioavailability was also seen with i.p.
administration in mice, and peak concentrations
were usually achieved by 30min.
Pharmacokinetics were linear up to doses of
78 mgkg-1 in mice, but became non-linear above
this. For example, at 650mgkg-1 peak plasma
concentrations (100jugml-1) were far less than
predicted from lower doses, and were maintained to
at least 6 h before declining slowly. Because of its
low solubility in aqueous solution benznidazole was
usually given as a suspension in 50% polyethylene
glycol, and this undoubtedly limited the absorption
rate and contributed to the slow clearance at high
doses. There may also be saturation of hepatic
metabolism, as seen with other lipophilic
nitroimidazoles (Workman & Brown, 1981). Since
only 5% of administered benznidazole was
recovered unchanged in the urine, the predominant
elimination mechanism is likely to be metabolism
although other mechanisms (e.g. biliary and faecal
excretion) cannot be excluded. Schwartz et al.
(unpublished) obtained evidence for the 2-hydroxy
"hydrolysis" product and the 2-amino reduction
product (see Schwartz & Hofheinz, 1982), and we
have also identified the amine metabolite (Walton
& Workman, in preparation). By analogy with
other nitroimidazoles it is likely that ring cleavage
also occurs (Schwartz & Hofheinz, 1982).
Tumour penetration by benznidazole was
generally good. For the transplantable tumours in
mice (KHT and EMT6) the average tumour/whole
plasma ratios ranged from 59-99%, and steady-
state ratios were about 90%. With the spontaneous
neoplasms in dogs tissue/whole plasma ratios
ranged from 14-70% and the overall mean was
50%. Nervous tissue penetration was generally
similar to that in tumours. Brain/whole plasma
ratios averaged 61-76% in the mouse and 42% in
the dog, while the mean peripheral nerve/whole
plasma ratio in the dog was 74%. Liver/whole
plasma ratios averaged 42 and 71% in the two
mouse strains studied, while the two values
obtained in the dog were 14 and 51%.
It may be useful to compare briefly the
pharmacokinetics of benznidazole with those of the
more familiar MISO (e.g. see Workman, 1980b and
1983). Although similar in electron affinity (redox
potential) benznidazole is considerably more
lipophilic (Adams et al., 1979), and lipophilicity has
a major effect on nitroimidazole pharmacokinetics
(see Workman, 1982b). Both exhibit non-linear
kinetics at very high doses in mice. At lower doses
both are absorbed quite rapidly after i.p. and oral
administration in mice and dogs, respectively. Peak
concentrations per unit dose were similar in mice,
and similar or higher for benznidazole in dogs. The
elimination t2 was longer for benznidazole in all
three species: 90min compared with 20-40min inPRECLINICAL PHARMACOKINETICS OF BENZNIDAZOLE 301
mice; 4-5 h compared with 40-60 min in sheep
(Miller, personal communication); and 9-11 h
compared with 4-5 h in large crossbred dogs. The
difference does not appear so large in humans in
whom Raaflub & Ziegler (1979) and Raaflub
(1980), using polarographic analysis after low
doses, found mean t-L values of 12-14h, only
slightly longer than the usual 10-12h average for
MISO. Both compounds are eliminated
predominantly by metabolism. The volume of
distribution for benznidazole in the dog was
0.53 1kg-1, which compares well with 0.621kg-
for MISO.
Tissue/whole plasma ratios tended to be rather
lower for benznidazole, possibly as a consequence
of its appreciable protein binding (39-59%) which
does not occur with MISO. The difference was
most obvious in the brain where the ratios for
benznidazole were 42% in dogs and 68% in mice
compared to respective values of 70% and 90% for
MISO. In EMT6 flank tumours the overall
tissue/whole plasma ratio was 69% for
benznidazole compared to 87% for MISO, but the
steady-state ratio was about 90% for both; in
spontaneous dog neoplasms the values were 50%
for benznidazole and 61% for MISO. The
difference was least in dog peripheral nerve (74%
for benznidazole and 82% for MISO).
We have shown recently that for the combination
of CCNU with misonidazole a major mechanism
appears to involve the inhibition of CCNU
metabolism by the sensitizer, probably in the liver,
resulting in elevated CCNU concentrations in
tumour but not normal tissues (Lee & Workman,
1983, 1984a). Benznidazole slows CCNU clearance
at much lower doses than misonidazole (Lee &
Workman, 1984b), is a considerably more potent
inhibitor of drug metabolising enzymes in vivo
(Workman et al., 1983) and exhibits more powerful
inhibition of CCNU hydroxylation by liver
microsome preparations in vitro (Lee & Workman,
unpublished): this explains the comparative potency
of benznidazole as a chemosensitizer with CCNU.
There may also be the additional mechanisms of
chemosensitization which require the presence of
the nitroimidazole in the tumour (see Brown, 1982;
Siemann, 1982). Whatever the mechanism, for the
clinical application of the benznidazole-CCNU
combination we should aim for whole plasma, liver
and tumour concentrations of nitroimidazole
similar to those associated with chemosensitization
in mice.
Clear enhancement of KHT tumour response to
CCNU can be obtained with i.p. benznidazole
doses at least as low as 13 mgkg-1 (Workman &
Twentyman, 1982) which would produce peak
whole plasma, liver and tumour concentrations of
about 104gml -1, 7jgg1- and 9pgg-', respectively.
Between 26 and 650 mgkg-1 the dose-response
curve becomes flat, with comparatively little gain in
chemosensitization at increasing doses; this is
almost certainly because the dose-peak whole
plasma concentration curve has the same shape
(Figure 4), with the plasma concentration increasing
by a factor of only four (from 20 pgml -1 to
90pgml-1) over the 25-fold dose range. The most
detailed chemosensitization work in mice has been
done with an i.p. benznidazole dose of 78 mgkg-1,
which gives whole plasma, liver and tumour
concentrations of 30pgml-1, 21 pgg-1 and
26 ugg-1, respectively. At this dose tumour
response is enhanced by a factor of 1.5-2 compared
to 1.2-1.4 in normal tissues, resulting in a net
therapeutic gain (Twentyman & Workman, 1983;
Siemann et al., 1983). On the other hand, the
results of Hirst et al. (1983) would indicate that this
therapeutic gain can be reduced when benznidazole
whole plasma concentrations are increased to
around 100pgml-1. Taken overall these data
suggest that for chemosensitization by benznidazole
in man we should probably aim for peak whole
plasma concentrations in the range 10-30pgml-1.
Because of its low aqueous solubility (and also
for convenience) benznidazole will be administered
orally in man. In large crossbred dogs we achieved
average peak whole plasma concentrations of 20
and 47pgml-1 with oral doses of 12.5 and
25mgkg-1 (Table I). For each mgkg-
I
administered the mean peak plasma concentration
was 1.77+0.17Mgml -1 (s.e., n=6), which compares
favourably with the value of 1.48 +0.06 (s.e., n=7)
obtained with oral administration at comparatively
low doses (mean 1.73 mgkg-1) in man (Raaflub &
Ziegler, 1979). Thus we predict that the target
concentrations of 10-30pgml-1 would be achieved
with oral doses of 6-20 mgkg-1 in man. In the
South American studies with benznidazole as an
antimicrobial agent, doses of 3-10 mgkg-1 were
given for 30-60 days (Barclay et al., 1978; Cerisola
et al., 1978; Coura et al., 1978; Fava et al., 1978).
With an average daily dose of 3.5 mgkg-1 the
mean steady state minimum and maximum plasma
concentrations were 8.3 +0.6 pgml-1 and
12.4+0.7pugml 1 (s.e., n=6) respectively. Side
effects were observed, including peripheral
neuropathy, but the schedule of 5mgkg-1 day -
for 30 days was considered well tolerated. For
chemosensitization purposes benznidazole would be
administered only intermittently with each CCNU
cycle, and peripheral neuropathy should be
avoided.
As far as the relative timing of CCNU and
benznidazole is concerned, our mouse studies have
shown that no advantage is gained by prolonged
exposure to the sensitizer (Twentyman &
Workman, 1983). We obtained peak concentrations302 P. WORKMAN et al.
3-5 h after oral dosing in dogs, which compares
favourably with the peak time of 3-4 h after low
doses in man (Raaflub & Ziegler, 1979).
A phase I clinical trial of benznidazole plus
CCNU, with associated pharmacokinetic studies, is
now underway in this Unit. Designed with the
above considerations in mind, this involves
escalating oral doses of benznidazole, commencing
at 8 mgkg-1, which are given 4h before
120mgm-2 CCNU orally once every 6 weeks.
We thank Dr Carey Smithen of Roche Products Ltd. for
supplies of benznidazole and Ro 07-0913, and Jane
Donaldson and Nancy Smith for excellent technical
assistance.
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